19,343 The Cooper Companies, Inc. $COO Shares Bought by International Assets Investment Management LLC

Key Points

• International Assets Investment Management increased its Cooper Companies stake by 506%, buying 19,343 shares and bringing its holdings to 23,166 shares, valued at about $1.31 million.
• Cooper Companies beat quarterly earnings expectations with EPS of $1.15 versus $1.12 estimated, though revenue of $1.07 billion fell short of the $1.10 billion consensus. The company authorized a $3 billion share repurchase plan.
• Analysts’ consensus rating is Hold, with an average price target of $68.60; recent insider purchases included 34,701 shares worth about $1.88 million over 90 days.

International Assets Investment Management LLC increased its stake in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 506.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,166 shares of the medical device company's stock after acquiring an additional 19,343 shares during the period. International Assets Investment Management LLC's holdings in Cooper Companies were worth $1,310,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Essential Partners LLC raised its position in Cooper Companies by 23.4% during the first quarter. Essential Partners LLC now owns 874 shares of the medical device company's stock valued at $62,000 after purchasing an additional 166 shares in the last quarter. Basecamp Wealth Advisors LLC boosted its holdings in shares of Cooper Companies by 20.8% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 1,557 shares of the medical device company's stock worth $111,000 after purchasing an additional 268 shares in the last quarter. Avalon Trust Co bought a new position in shares of Cooper Companies during the 2nd quarter valued at about $25,000. Elevation Wealth Partners LLC increased its position in shares of Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company's stock valued at $29,000 after purchasing an additional 375 shares during the last quarter. Finally, New Mexico Educational Retirement Board increased its position in shares of Cooper Companies by 4.3% during the 2nd quarter. New Mexico Educational Retirement Board now owns 9,700 shares of the medical device company's stock valued at $696,000 after purchasing an additional 400 shares during the last quarter. Institutional investors own 24.39% of the company's stock.

Cooper Companies Stock Performance

NASDAQ COO opened at $60.83 on Wednesday. The company has a 50-day simple moving average of $59.73 and a two-hundred day simple moving average of $68.89. The Cooper Companies, Inc. has a 12-month low of $51.01 and a 12-month high of $89.83. The firm has a market cap of $11.57 billion, a price-to-earnings ratio of 20.76, a PEG ratio of 2.41 and a beta of 0.83. The company has a quick ratio of 0.73, a current ratio of 1.22 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the previous year, the business earned $0.49 earnings per share. The company's quarterly revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities analysts forecast that The Cooper Companies, Inc. will post 4.53 EPS for the current year.

Cooper Companies declared that its Board of Directors has approved a stock repurchase plan on Wednesday, September 9th that permits the company to repurchase $3 billion in shares. This buyback authorization permits the medical device company to buy up to 22.7% of its shares through open market purchases. Share buyback plans are often an indication that the company's management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on COO. Mizuho set a $75.00 price objective on Cooper Companies and gave the company an "outperform" rating in a report on Thursday, September 10th. Citigroup reaffirmed a "neutral" rating and issued a $60.00 target price (down from $80.00) on shares of Cooper Companies in a research note on Thursday, September 10th. Robert W. Baird set a $61.00 price target on shares of Cooper Companies and gave the company a "neutral" rating in a research report on Thursday, September 10th. Piper Sandler reiterated a "neutral" rating on shares of Cooper Companies in a research report on Thursday, October 15th. Finally, William Blair downgraded shares of Cooper Companies from an "outperform" rating to a "market perform" rating in a research note on Thursday, September 10th. Four equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $68.60.

Insider Transactions at Cooper Companies

In other news, Director Lawrence Kurzius purchased 10,000 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was bought at an average cost of $53.91 per share, for a total transaction of $539,100.00. Following the acquisition, the director directly owned 21,099 shares of the company's stock, valued at $1,137,447.09. This represents a 90.10% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Walter M. Rosebrough, Jr. purchased 7,000 shares of the company's stock in a transaction on Friday, September 11th. The shares were purchased at an average cost of $54.11 per share, with a total value of $378,770.00. Following the transaction, the director directly owned 17,000 shares in the company, valued at $919,870. This trade represents a 70.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have bought 34,701 shares of company stock worth $1,880,039. Insiders own 2.08% of the company's stock.

Cooper Companies Profile

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women's health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.